Interventional Cardiology: Peripheral Vascular Disease Therapeutic Devices
The 2019 combined global prevalence of peripheral vascular disease (PVD) was more than 113 million, with an incidence of 10.5 million and over 74,000 related deaths. Global sales of PVD therapeutic devices were estimated at $5.3bn in 2021. Market drivers include the increasing elderly population and its associated increase in PVD prevalence, a growing preference for minimally invasive therapies, and a preference for technologies that reduce healthcare costs and reduce hospital lengths of stay. Limiters to this market include device cost, lack of routine screening for PVD, regulatory barriers to market entry, and the threat of ongoing COVID-19 restrictions and supply chain issues worldwide.
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for PVD therapeutic devices; these include percutaneous transluminal angioplasty devices, vascular stents, atherectomy devices, thrombectomy devices, and chronic total occlusion crossing devices. Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2021–26.
Related Medtech Insight articles:
- Latest Medicare Data Suggests No Heightened Death Risk For Paclitaxel-Coated Devices
- Abbott Focuses On Improving Early Diagnosis Of Vascular Disease To Improve Outcomes
- FDA Re-Finalizes Peripheral Vascular Atherectomy Devices Guidance After Key Updates
- Subscribe to Medtech Insight to view these articles and more!